Article ; Online: NMR Metabolomics of Primary Ovarian Cancer Cells in Comparison to Established Cisplatin-Resistant and -Sensitive Cell Lines.
2024 Volume 13, Issue 8
Abstract: Cancer cell lines are frequently used in metabolomics, such as in vitro tumor models. In particular, A2780 cells are commonly used as a model for ovarian cancer to evaluate the effects of drug treatment. Here, we compare the NMR metabolomics profiles of ... ...
Abstract | Cancer cell lines are frequently used in metabolomics, such as in vitro tumor models. In particular, A2780 cells are commonly used as a model for ovarian cancer to evaluate the effects of drug treatment. Here, we compare the NMR metabolomics profiles of A2780 and cisplatin-resistant A2780 cells with those of cells derived from 10 patients with high-grade serous ovarian carcinoma (collected during primary cytoreduction before any chemotherapeutic treatment). Our analysis reveals a substantial similarity among all primary cells but significant differences between them and both A2780 and cisplatin-resistant A2780 cells. Notably, the patient-derived cells are closer to the resistant A2780 cells when considering the exo-metabolome, whereas they are essentially equidistant from A2780 and A2780-resistant cells in terms of the endo-metabolome. This behavior results from dissimilarities in the levels of several metabolites attributable to the differential modulation of underlying biochemical pathways. The patient-derived cells are those with the most pronounced glycolytic phenotype, whereas A2780-resistant cells mainly diverge from the others due to alterations in a few specific metabolites already known as markers of resistance. |
---|---|
MeSH term(s) | Humans ; Female ; Cisplatin/pharmacology ; Ovarian Neoplasms/metabolism ; Ovarian Neoplasms/pathology ; Ovarian Neoplasms/drug therapy ; Metabolomics/methods ; Drug Resistance, Neoplasm ; Cell Line, Tumor ; Magnetic Resonance Spectroscopy/methods ; Metabolome/drug effects ; Antineoplastic Agents/pharmacology |
Chemical Substances | Cisplatin (Q20Q21Q62J) ; Antineoplastic Agents |
Language | English |
Publishing date | 2024-04-09 |
Publishing country | Switzerland |
Document type | Journal Article ; Research Support, Non-U.S. Gov't ; Comparative Study |
ZDB-ID | 2661518-6 |
ISSN | 2073-4409 ; 2073-4409 |
ISSN (online) | 2073-4409 |
ISSN | 2073-4409 |
DOI | 10.3390/cells13080661 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.